Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.

12 Feb 2010

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."

12 Feb 2010

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).

11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

AmerisourceBergen offers rapid implementation methodology for meaningful use of EHRs

AmerisourceBergen announced a unique offering designed to help hospitals and health systems achieve meaningful use readiness for electronic health records (EHR), regardless of the technology they are using.

8 Feb 2010

AMAG Pharmaceuticals releases safety update on Feraheme Injection

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today provided a safety update on Feraheme® (ferumoxytol) Injection for intravenous use.

6 Feb 2010

Research could help in developing protein-based vaccine against maternal malaria

Researchers at the University of Copenhagen have become the first in the world to synthesize the entire protein that is responsible for life-threatening malaria in pregnant women and their unborn children.

5 Feb 2010

News piece may highlight the importance of cord blood donation among Hispanic and Latino community

CORD:USE Cord Blood Bank and its program at South Miami Hospital are being featured on CNN en Espanol's show "Salud." This story on the importance of cord blood donation aired this week and can be seen Friday, February 5 at 9:30 a.m. EST and Sunday, February 7 at 9 a.m. EST and 3 p.m. EST on CNN en Espanol.

5 Feb 2010

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

Protalix Biotherapeutics, Inc. today announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, February 10-12, 2010 in Miami, Florida.

5 Feb 2010

Sequenom CMM launches SensiGene Fetal RHD Genotyping test for pregnant RhD negative women

Sequenom, Inc. today announced the launch of the SensiGene™ Fetal RHD Genotyping test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM).

5 Feb 2010

Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium

Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement therapy (ERT) in development for the treatment of Type 1 Gaucher disease, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami, Florida.

4 Feb 2010

New study to investigate preventative programmes for anaemia control in young women

A new study led by LSTM will investigate whether long-term weekly iron and folic acid supplementation can reduce anaemia without increasing the risk of contracting malaria.

3 Feb 2010

Entelos awarded U.S. patent for apparatus and methods of assessing metabolic substrate utilization

Entelos, Inc., a simulation and modeling company focused on human health, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,654,955 entitled “Apparatus and Methods for Assessing Metabolic Substrate Utilization” to the Company. These methods further strengthen the Entelos® Metabolism PhysioLab® platform and leverage insights about human physiology that can lead to improved diagnosis, clinical testing, and personalized treatment across a highly variable patient population.

2 Feb 2010

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled data from all trials, less than one percent of treated patients developed product-specific antibodies. None of the antibodies neutralized native coagulation proteins.

2 Feb 2010

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. announced today that, in connection with the New Drug Application (NDA) filed by the Company in December 2009 for taliglucerase alfa for the treatment of Gaucher disease, the U.S. Food and Drug Administration (FDA) has requested additional data regarding the Chemistry, Manufacturing and Controls (CMC) section of the NDA.

2 Feb 2010

DATATRAK International announces multi-center study on Renal Anemia

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the contract signing for a Phase IV, eight-year, 500-site, 5,000-patient study worth approximately $900,000 with a global specialty pharmaceutical and medication delivery company.

2 Feb 2010

DSG’s eCaseLink EDC system employed in clinical trials for treatment of chronic kidney disease

DSG’s eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current phase 2 and phase 2a clinical trials for treatments of progressive and chronic kidney disease.

1 Feb 2010

ASH offers hematologists a new resource for earning CME credits

The American Society of Hematology (ASH) now offers physicians who diagnose and treat blood disorders a new resource for earning continuing medical education (CME) credits while staying abreast of the latest clinical strategies in the rapidly changing field of hematology.

29 Jan 2010

Researchers discover new target for drugs to prevent common iron deficiency

The discovery of a major player in the body's regulation of iron levels should provide a new target for drugs that prevent common iron deficiency as well as rare, potentially deadly iron overload, researchers said.

29 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Anemia News and Research

Further Reading

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

AmerisourceBergen offers rapid implementation methodology for meaningful use of EHRs

AMAG Pharmaceuticals releases safety update on Feraheme Injection

Research could help in developing protein-based vaccine against maternal malaria

News piece may highlight the importance of cord blood donation among Hispanic and Latino community

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

Sequenom CMM launches SensiGene Fetal RHD Genotyping test for pregnant RhD negative women

Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium

New study to investigate preventative programmes for anaemia control in young women

Entelos awarded U.S. patent for apparatus and methods of assessing metabolic substrate utilization

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

DATATRAK International announces multi-center study on Renal Anemia

DSG’s eCaseLink EDC system employed in clinical trials for treatment of chronic kidney disease

ASH offers hematologists a new resource for earning CME credits

Researchers discover new target for drugs to prevent common iron deficiency

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News